International Stem Cell Corporation (OTCBB: ISCO) (www.internationalstemcell.com)
has announced new sales and marketing initiatives for its Lifeline Skin
Care products (www.lifelineskincare.com).
These efforts are designed to enable Lifeline to robustly, strategically
and profitably grow the business.
Consumer Advertising
During June and July, new integrated advertising campaigns will be
launched in three marketing channels-online, in newspapers and
magazines, and through direct mail. The campaigns will feature
Lifeline's innovative stem cell technology and proof of the brand's
potential: younger looking skin. Although the ads will eventually be
national in reach, the first few months will be devoted to optimizing
the creative approach, targeting, frequency, timing, positioning, offer
and ROI.
Key Opinion Leader and Peer Group Influencer
Elizabeth K. Hale, MD, one of the nation's top dermatologists, is now
endorsing Lifeline Skin Care to both consumer and trade audiences. Dr.
Hale is an Associate Clinical Professor of Dermatology at New York
University, a private practitioner and a guest of the Doctor Oz show,
the Today Show and Good Morning America. During the week of June 4 she
met with beauty editors for Prevention, Health, Town and Country,
Allure, FoxNews.com and InStyle, to present Lifeline Skin Care and its
unique technology. The endorsement of a leading dermatologist should not
only enhance the credibility of the brand but increase its visibility.
Strategic Partners
Email campaigns through strategic partners have been very successful at
marketing Lifeline products. To expand that effort, several new key
opinion leaders have now agreed to endorse Lifeline Skin Care to their
social networks, including Mrs. Jeri Thompson, a conservative
spokesperson, radio and TV guest and advocate for non-embryonic stem
cell research; and authors, experts and media personalities in the areas
of women's health, yoga, cosmetic dentistry, and retirement planning.
Many of these partners plan to market Lifeline through their social
network (email marketing, blogs, Facebook, etc.) as well as through
personal and radio appearances. Most of these campaigns will launch
during the third quarter.
Professional Channels
During the week of June 12, Lifeline is launching two campaigns directed
to 27,000 cosmetic dermatologists and day spas. These campaigns are
focused on providing information to skin care professionals, including
dermatologists and plastic surgeons, to understand and embrace the
significance and value of stem cell extracts for skin rejuvenation.
Donna Queen, newly appointed President and CEO of Lifeline Skin Care,
said, "There is an enormous opportunity for us in skin care and we're
now prepared to commit the people, energy and resources. We intend to
take the leadership role and intend to make Lifeline own the stem cell
skin care category. Effective immediately, we are accelerating and
expanding our marketing and sales efforts to increase awareness and
drive sales.
"Increasing awareness of Lifeline's unique technology will enable us to
stand apart and ahead in the anti-aging category. Stem cell skin care is
still in a nascent phase, it's time for us to seize the opportunity,"
continued Ms. Queen.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic
applications of human parthenogenetic stem cells (hpSCs) and the
development and commercialization of cell-based research and cosmetic
products. ISCO's core technology, parthenogenesis, results in the
creation of pluripotent human stem cells from unfertilized oocytes
(eggs). hpSCs avoid ethical issues associated with the use or
destruction of viable human embryos. ISCO scientists have created the
first parthenogenic, homozygous stem cell line that can be a source of
therapeutic cells for hundreds of millions of individuals of differing
genders, ages and racial background with minimal immune rejection after
transplantation. hpSCs offer the potential to create the first true stem
cell bank, UniStemCell™. ISCO also produces and markets specialized
cells and growth media for therapeutic research worldwide through its
subsidiary Lifeline Cell Technology (www.lifelinecelltech.com),
and stem cell-based skin care products through its subsidiary Lifeline
Skin Care (www.lifelineskincare.com).
More information is available at www.internationalstemcell.com
or follow us on Twitter @intlstemcell.
To receive ongoing corporate communications, please click on the
following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
Forward-looking Statements
Statements pertaining to anticipated developments, the potential
benefits of sales and marketing initiatives, and other opportunities for
the company and its subsidiaries, along with other statements about the
future expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, competitive conditions and developments,
the need and ability to obtain future capital, application of capital
resources among competing uses, and maintenance of intellectual property
rights. Actual results may differ materially from the results
anticipated in these forward-looking statements and as such should be
evaluated together with the many uncertainties that affect the company's
business, particularly those mentioned in the cautionary statements
found in the company's Securities and Exchange Commission filings. The
company disclaims any intent or obligation to update forward-looking
statements.
International Stem Cell Corporation
Dr. Simon Craw, Executive Vice
President Business Development
760-940-6383
ir@intlstemcell.com
or
Investor
Relations:
MZ Group
Mark McPartland
212-301-7130
markmcp@mzgroup.us
www.mz-ir.com